Guest Dr. Paul Dobesh discusses the Caravaggio trial and DOAC use for VTE management in patients with cancer.
0:00-0:40: Intro
0:41-1:35: Introduction of Dr. Paul Dobesh
1:36-4:02: Caravaggio trial overview
4:03-7:08: Background of VTE antithrombotic management in cancer 7:09-9:09: Overall thoughts and where apixaban fits
9:10-10:42: ADAM-VTE Trial
10:43-13:36: Bleeding
13:37-14:37: PROBE trial design
14:38-15:47: Approach the VTE antithrombotic management in cancer patients
15:47-16:34: Closing
References:
- Caravaggio trial: Agnelli G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 2020;382:1599-1607.
- CLOT trial: Lee AY, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2):146-53.
- ADAM VTE trial: McBane RD, et al. Apixaban, dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial. Blood 2018;132(1):421.
- Hokusai VTE trial: Raskob GE, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018;378(7):615-624.
- SELECT-D trial: Young AM, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 2018;36(20):2017-2023.
CardioScripts 